Compare Eli Lilly And Co (LLY) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Tesla, Inc. — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Tesla, Inc. trades at $382.49 (market cap $1.48T). The key difference: Tesla, Inc. is the larger of the two by market cap, and Eli Lilly And Co pays a 0.59% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Tesla, Inc. for 88 Days on average.
| LLY | TSLA | |
|---|---|---|
Market Cap | $1.04T | $1.48T |
Volume | 3,064,878 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $489.88 |
52-Week Low | $799.57 | $298.16 |
Typical Hold Time | 93 Days | 88 Days |
Enterprise Value | $1.09T | $1.45T |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Tesla (TSLA) trades at $382.70, up 1.35% today, with a bullish technical signal from moving averages but mixed oscillators. The stock faces high valuation multiples (P/E 347.22, P/S 12.8) amid declining profitability, with net income margin falling to 3.67% in 2025. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, though Q2 2026 earnings missed expectations.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and competitive pressures. The consensus price target of $441.36 suggests upside, but investors must weigh high valuation, margin compression, and volatile cash flows. Key catalysts include robotaxi progress and demand recovery, while risks involve execution delays and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
